{
    "organizations": [],
    "uuid": "0a46992a54542a410abff6545031db1f9444b98a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dare-bioscience-enters-into-a-lice/brief-dare-bioscience-enters-into-a-license-agreement-with-strategic-science-and-technologies-idUSFWN1Q210L",
    "ord_in_thread": 0,
    "title": "BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Dare Bioscience Inc:\n* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES\n* DARE BIOSCIENCE INC - AGREEMENT TO LICENSE SST-6007 (5PCT TOPICAL SILDENAFIL CITRATE CREAM), FROM STRATEGIC SCIENCE & TECHNOLOGIES, LLC Source text: ( bit.ly/2H5LWjg ) Further company coverage:\n ",
    "published": "2018-02-12T20:13:00.000+02:00",
    "crawled": "2018-02-13T15:40:59.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "dare",
        "bioscience",
        "inc",
        "feb",
        "co",
        "entered",
        "license",
        "agreement",
        "strategic",
        "science",
        "strategic",
        "science",
        "technology",
        "dare",
        "bioscience",
        "inc",
        "agreement",
        "license",
        "5pct",
        "topical",
        "sildenafil",
        "citrate",
        "cream",
        "strategic",
        "science",
        "technology",
        "llc",
        "source",
        "text",
        "company",
        "coverage"
    ]
}